AstraZeneca’s Alexion subsidiary is snapping up a suite of Pfizer’s preclinical gene therapies in a move to expand its toolkit in rare disease R&D.
The deal, which the companies said is worth up to $1 billion, was unveiled as AstraZeneca also announced that Mene Pangalos will step down as EVP, BioPharma R&D. Succeeding him in that role early next year — and joining the senior executive team in a few days — will be Sharon Barr, the current head of research and product development at Alexion.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters